SHARE

Shares of StemCells Inc (NASDAQ:STEM) ended Monday session in red amid volatile trading. The shares closed down -0.031 points or -3.80% at $0.779 with 306,206 shares getting traded. Post opening the session at $0.80, the shares hit an intraday low of $0.70 and an intraday high of $0.80 and the price vacillated in this range throughout the day. The company has a market cap of $8.62 million and the numbers of outstanding shares have been calculated to be 16.26 million shares.

StemCells Inc (STEM) engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The companys HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has completed a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis. Its HuCNS-SC is also in Phase I/II clinical trials for the treatment of thoracic spinal cord injury; Phase II clinical trials for the treatment of cervical spinal cord injury; and Phase I/II clinical trials for dry age-related macular degeneration. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

Shares of Mylan NV (NASDAQ:MYL) ended Monday session in red amid volatile trading. The shares closed down -0.69 points or -1.86% at $36.50 with 5.47 million shares getting traded. Post opening the session at $37.29, the shares hit an intraday low of $36.48 and an intraday high of $37.48 and the price vacillated in this range throughout the day. The company has a market cap of $19.52 billion and the numbers of outstanding shares have been calculated to be 534.91 million shares.

Mylan NV (MYL) announced the U.S. launches of the first generic versions of Daiichi Sankyo’s Benicar® and Benicar HCT®, Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, and Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg, respectively. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for these products.

Olmesartan Medoxomil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure. Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for the treatment of hypertension to lower blood pressure, and are not indicated for the initial therapy of hypertension.

Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, had U.S. sales of approximately $1 billion for the 12 months ending August 31, 2016, according to IMS Health. Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg had U.S. sales of approximately $805 million during that same time.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here